<DOC>
	<DOCNO>NCT00976105</DOCNO>
	<brief_summary>The overall purpose study see whether drug safe well tolerate give overweight obese otherwise healthy volunteer 10 day . Up 4 group people give drug variable strength . The blood level drug measure effect mood cognition ( mental process involve awareness , learn judgement ) assesed .</brief_summary>
	<brief_title>Effects Repeat Dosing GSK1521498</brief_title>
	<detailed_description>This study test new drug may use treat eat behaviour pattern overweight obese patient find difficult control . The drug work inhibit effect messenger molecule call opioids , e.g . endorphin . These opioids naturally produce within human body control hunger , thirst , pleasurable feeling relate eat food . The drug attach opioid bind site brain , know mu-opioid receptor ; block natural effect opioids may reduce crave eat fatty sugary food . Single dose drug give human show safe . Now drug give every day 10 day check drug safe tolerate give repeatedly . The study two part : Part A : people receive sleep tablet make sleepy ( dummy drug ) complete questionnaire simple test include computer exercise test effect tablet mood cognition . This information use help judge happen Part B . Part B : require stay unit 10 day receive tablet every day complete questionnaire test check mood cognitive change . Various assessment include effect eat behaviour , pain measure change body composition ( content fat , muscle water ) .</detailed_description>
	<mesh_term>Zolpidem</mesh_term>
	<mesh_term>Hypnotics Sedatives</mesh_term>
	<criteria>Healthy determine responsible experienced physician Non smoke male female 18 60 year age inclusive A female subject childbearing potential must use contraception method list protocol prior start dose least 14 day receive last dose study medication . Male subject must agree use one contraception method list protocol first dose study medication least 84 day receive last dose study medication . BMI within range 25 35 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB QTcF &lt; 450 msec . Suitable repeat cannulation . Has clinically significant rhythm abnormality identify 24hour screen Holter assessment . Systolic blood pressure great 150 mmHg and/or diastolic BP great 90 mmHg . Diabetes mellitus physiciandiagnosed dyslipidaemia require treatment Selfadministered Beck Depression Inventory II scale total score great 13 suicide question score great zero screening . Positive prestudy drug/alcohol screen Positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Positive test HIV antibody . Pregnant lactating female Smoking history include regular use tobacco nicotinecontaining product within 6 month prior screen . A history thyroid dysfunction abnormal thyroid function test History regular high level alcohol consumption within 6 month study Participated clinical trial involve investigational product within 90 day Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day prior first dose study medication History gastrointestinal hepatic condition procedure could affect absorption investigational product . History sensitivity study medication , component thereof history drug allergy contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Unwillingness inability follow procedure outline protocol , include abstain consumption caffeineor xanthine containing product 24 hour prior dose postdose assessment , use illicit drug , refrain alcohol 24 hour prior dose final postdose assessment , , consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication collection final pharmacokinetic blood sample . Any finding would preclude safe use Echo MRI scan . These include : history panic attack and/or claustrophobia , pacemaker , implant hearing aid , metallic body pierce and/or metal implant remove , opinion Investigator subject exceeds size limitation instrument . Mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Repeat dose</keyword>
	<keyword>Personality trait</keyword>
	<keyword>Fat mass</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>